34 results about "Hematopoietic growth factor" patented technology

The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

The invention provides a culture system for hematopoietic stem cell amplification. The culture system comprises a basal culture medium and a composition for promoting hematopoietic stem cell amplification, and the composition contains early hematopoietic growth factors related to hematopoietic regulation. The invention further provides a method adopting the culture system for in-vitro amplification of hematopoietic stem cells and a kit comprising the composition for promoting hematopoietic stem cell amplification. By adopting the culture system for in-vitro amplification of the hematopoietic stem cells, the hematopoietic stem cells can be amplified by more than hundreds of times, so that the problem of hematopoietic stem cell insufficiency in the process of treating blood system diseases can be solved effectively.

A hematopoietic growth factor delivery composition includes a hematopoietic growth factor, a liquid vehicle, a first biocompatible polymer and a second biocompatible polymer. The composition exhibits reverse-thermal viscosity behavior, due to interaction between the first biocompatible polymer and the liquid vehicle. The second biocompatible polymer helps to protect the first biocompatible polymer from being dissolved in vivo following administration to a host.

The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.

A screening method for identifying mutant polypeptides having at least one amino acid difference from a wild type protein involved in a receptor-ligand interaction is disclosed. Also disclosed are mutant polypeptides of the hematopoietic growth factor flt3-Ligand (flt3-L) identified using this method, nucleic acids encoding these flt3-L mutant polypeptides, and methods of treatment involving in vitro and in vivo use of the mutant polypeptides and nucleic acids.

The invention pertains to methods and devices for the long term, in vitroculture of hematopoietic progenitor cells in the absence of exogenously added hematopoietic growth factors, improved methods for the introduction of foreign genetic material into cells of hematopoietic origin, and to apparatus for performing these methods. The hematopoietic progenitor cells are cultured on a three-dimensional porous biomaterial. The three-dimensional porous biomaterial enhances hematopoietic progenitor cell survival and leads to an expansion of progenitor cell numbers and/or functionality, while maintaining progenitor cell pluripotency in the absence of exogenous growth factors. In addition, the three-dimensional porous biomaterial supports high level transduction on cells cultured upon such environment.

The present invention is directed to new methods for treating a subject in need of hematopoietic stimulation. The present invention is also directed to new methods of neutrophil stimulation in a subject in need thereof. The present invention is also directed to new methods of platelet stimulation in a subject in need thereof. The methods comprise administering to the subject an effective amount of a peptide optionally in combination of a hematopoietic growth factor, wherein the peptide is:

• • (i) Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Xaa-Leu-Gln-Asp-Val-NH₂ (SEQ ID NO: 1), where Xaa=Lys, Leu, Ile, Nle or Met, preferably Xaa=Lys; or
  • (ii) Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Xaa-Leu-Gln-Asp-Val-Y (SEQ ID NO: 2), cyclized in the form of a lactam between Glu²² and Lys²⁶,
    • Xaa=Leu, Ile, Nle or Met,
    • Y=NH₂ or OH.
    • Preferably, Xaa is Leu and Y is NH₂.

The invention provides a serum-free medium and a method for amplifying hematopoietic stem cells. The serum-free culture medium comprises a serum-free basal culture medium, cytohormone, an umbilical cord mesenchymal stem cell conditioned culture medium and auxiliary components. The cytohormone comprises a stem cell factor, thrombopoietin and a hematopoietic growth factor Flt3 ligand. The umbilicalcord mesenchymal stem cell conditioned medium is derived from cultured human umbilical cord mesenchymal stem cells. The auxiliary components comprise vitamin C, vitamin E or a combination of vitamin Cand vitamin E.

The invention relates to a series of peptides capable of promoting the propagation of marrow karyocyte and marrow stroma cell, and its application, its biological activity is superior to the existing hematopoiesis growth factors, and has the advantages of simplified production process and stabilized effect. The medicament can be used for effectively treating panhematopenia for patients with regenerative anemia and cancer.

Embodiments of the present disclosure concern improvements to cell therapy for cancer. In certain embodiments, an immune cell lacks expression of hematopoietic growth factor receptor c-MPL (myeloproliferative leukemia), the receptor for thrombopoietin (TPO), and supplementation of this effect allows an improvement for cancer cell therapy, including of hematological malignancies. In specific embodiments, immune cells comprise recombinant c-MPL expression or parts thereof and the cells have enhanced co-stimulation and cytokine signals and improved activation, persistence, and anti-tumor function compared to cells that lack recombinant c-MPL expression.

The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders, particularly bone and breast cancer, because it acts to suppress the proliferating cells.

The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of chemotherapy-induced aplasia.

The present disclosure provides methods of treating neuroblastoma using an anti-GD2 antibody, at least one chemotherapeutic agent, and at least one hematopoietic growth factor. The present disclosure also provides compositions for treating neuroblastoma.